Abstract
THE FIVE-STORY FACILITY near the Rhine River in Pratteln, Switzerland, can be viewed as a monument to a gamble that didn't pay off. Granted, it was in a game—contract drug manufacturing in the early 2000s—where not many came out ahead. Eight years after losing a big bet, however, Building 40, as it's called, is back at the table. Rohner, a chemical company with a long heritage in dyes, built the facility as a vehicle for reinventing itself as a fine chemicals maker to serve pharmaceutical companies—especially those in the nearby Basel neighborhood such as Roche, Novartis, and Ciba-Geigy. The plant, an expensive oddity with shiny hardwood floors, filled up nicely. But Rohner had just a few big customers. And when one was acquired in 2003 and its new owner pulled manufacturing in-house, Rohner lost the majority of its business. The crisis was followed by a change of hands in 2004, when Novasep, a French ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
